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mates for virological response (VR; viral load levels50 copies/ml), immunorecov-
ery (change in CD4 cells/l from baseline to week 96), incidence of diarrhea, nausea
and rash were generated by Bayesian mixed treatment comparison (MTC). Point
estimates were reported with corresponding 95% credible intervals. RESULTS: In
total, 6 unique studies and 2 study extensions were included; consisting of 3 ATV/r,
1 DRV/r, 5 LPV/r, and 5 EFV treatment arms. Pooled MTC estimates for VR at week
48 were 77.7% (95%CrI: 74.1%-81.1%) for ATV/r, 76.4% (72.9%-79.7%) for EFV, 74.7%
(67.2%-81.2%) for DRV/r, and 72.5% (69.9%-75.0%) for LPV/r. The ratio of the propor-
tion of patients with VR at week 96 versus week 48 was estimated at ATV/r: 0.934
(0.872-0.999), DRV/r: 0.918 (0.807-1.041), EFV: 0.908 (0.834-0.981) and LPV/r: 0.878
(0.827-0.929). Immunorecovery was 254.9 (245.2-264.9) cells/l for LPV/r, 238.1
(219.5-257.0), 225.2 (209.6-241.3), and 206.1 (190.3-222.4) for DRV/r, ATV/r and EFV
respectively. The incidence of diarrhea was 10.7% (8.7%-12.8%) for LPV/r, compared
to 4.5% (2.3%-7.4%), 2.3% (0.3%-7.0%), and 2.1% (1.0%-3.7%) for DRV/r, EFV, and
ATV/r respectively. The incidence of nausea and rash did not differ markedly
among the treatments. CONCLUSIONS: The estimates for efficacy and tolerability
suggest all 4 ARV treatments are valuable options in treatment-naive HIV patients,
with ATV/r’s sustained viral response bringing added value. This MTC provides a
useful framework for ARV treatment comparison for HTA and clinical decision
making.
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OBJECTIVES:To systematically assess the clinical and economic burden of invasive
fungal infection (IFI) in Europe and to understand the value and treatment out-
comes of diagnostic and empirical therapeutic approaches. METHODS: A compre-
hensive literature review was conducted using PubMed/MEDLINE and EMBASE
(past 10 years) and relevant clinical societies (last 5 years) to identify epidemiology,
outcomes, and treatment trends focusing on invasive Aspergillus and Candida
infections using a defined protocol for inclusion/exclusion and data collection met-
rics. Clinical and economic burden outcomes described were incidence, mortality,
overall healthcare resource utilization, length of hospital stay, and costs for IFI.
RESULTS: Of 370 abstracts screened, 57 primary literature articles and 18 clinical
society abstracts met inclusion criteria providing data from 12 European countries.
No studies were identified in Eastern Europe and only two randomized, controlled
studies comparing pre-emptive to empirical treatment were found. IFI incidence
ranged from 3%-8% in empirical vs 8%-9% in pre-emptive treatment. Overall (IFI
attributable) mortality ranged from 5%-41% (0%-24%) and 2%-17% (0%-13%) for
non-comparative vs comparative studies, respectively. The highest mortality was
found among critically ill patients, pediatric, and those with hematologic malig-
nancies. The cost of IFI ranged from €8,351-€11,821 when evaluating hospitaliza-
tions and antifungals to €26,596-€49,216 when all direct costs for management
were included. Costs for antifungal therapy alone were €3,930-€7,314. The incre-
mental cost burden of IFI ranged from €10,530-€51,033 depending on the certainty
of infection (possible, probable, proven) and duration of follow up. CONCLUSIONS:
IFI represents a substantial clinical and economic burden in critically ill and im-
munocompromised patients in Europe. IFI may account for up to 24% of mortality
in these high risk populations and increase length of hospitalization by 20%. Dif-
ferentiation of outcomes for pre-emptive and empirical treatment strategies have
not been well defined and should be the focus of future clinical studies.
PIN5
PATIENT AND CLINICIAN PERCEIVED BENEFIT OF EARLY CONSUMPTION OF
FAMCICLOVIR FOR THE TREATMENT OF HERPES OUTBREAKS
Twiss J1, Mckenna S2, Bloch M3, Bonney MA4
1Galen Research Ltd, Manchester, UK, 2Galen Research Ltd, Manchester, UK, UK, 3Holdsworth
House Medical Practice, Darlinghurst, Australia, 4Novartis Pharmaceuticals Australia, North
ryde, NSW, Australia
OBJECTIVES: The aim of the study was to conduct secondary analyses of trial data
to determine whether taking famciclovir within 12 hours of first perceiving the
symptoms of genital herpes was related to decreased outbreak severity and im-
proved healing. METHODS: Data were derived from a double-blind, randomised,
active-controlled study of patient-initiated therapy comparing a 2-day course of
famciclovir with a 5-day course (total dose 1,50 mg in both courses) in adults with
genital herpes. Patients completed the Herpes Symptoms Checklist (HSC) on each
day of the five day study period. The proportion of patients healed (without lesions)
at day 5 was also determined. RESULTS: Data were available for 501 patients
(male  58.5%; mean age (sd)  39.2 (11.6) yrs). For the combined treatment
groups, patients who took their medication within 12 hours had significantly
lower HSC scores on day 1 (within 12 hours, median HSC6; above 12 hours,
median HSC8; Mann-Whitney U12,733.5, p0.05). Patients who took their
medication within 12 hours also had significantly lower HSC area under the
curve scores for the 5 day study period (AUC; within 12 hours, median HSC3.8;
above 12 hours, median HSC5.1; Mann-Whitney U12,751.0, p0.05). These
differences were not apparent for the treatment groups separately. There was a
significant association between the time at which the patients took their med-
ication and whether or not they were healed at day 5 for the combined sample
(Chi-square  4.95, p0.05). This finding was also observed for the 2-day treat-
ment group (Chi-square6.11, p 0.05) but not for the 5-day treatment group
(Chi-square0.49, p0.48). CONCLUSIONS: Taking famciclovir within 12 hours of
first becoming aware of genital herpes symptoms is associated with decreased
symptom severity and speed of healing. The 2-day treatment, when taken within
12 hours, is associated with a higher rate of healing by day 5.
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OBJECTIVES: In Turkey, lamivudine (LAM) is the only reimbursed antiviral (AV)
agent for the treatment of chronic hepatitis B (CHB) patients with HBV-DNA level
107 copies/mL. According to local reimbursement guideline, Tenofovir (TDF)
should be added in case of non-response at week24, or when viral resistance is
observed. This study aimed to compare the long-term clinical outcomes of enteca-
vir (ETV) with the current reimbursement approach (LAM monotherapy or LAM
with add-on TDF as rescue) in this patient subgroup. METHODS: Analysis popula-
tion included patients (n1000; 35% HBeAg-positive; 35 years old) without com-
pensated or decompensated cirrhosis (CC or DC) or hepatocellular cancer (HCC) at
model entry. Daily dose of AVs compared were (1) ETV 0.5mg, (2) LAM 100mg and (3)
LAM 100mg  add-on TDF 300mg when non-response or viral resistance occurs. A
decision-tree model with 5 parallel pathways for different levels of HBV-DNA with
a time horizon of 10 years was built. Major clinical outcomes included mortality
and life-years lost (LYL). RESULTS: Monotherapy with LAM during 10 years, re-
sulted in 198CC, 8.9DC and 66HCC cases . Addition of TDF to LAM in case of non-
response or viral resistance, reduced these cases to 78, 3.6 and 24 patients, respec-
tively. ETV treatment resulted in 24, 0.9 and 7.5 avoided cases of CC, DC and HCC,
respectively. While 108 deaths are estimated with LAM monotherapy (1,916LYL), in
the LAM plus TDF approach, the number of death will decrease to 44 (794LYL). ETV
treatment will further improve the results with additional avoidance of 15 deaths
(275LYL). The advantage of ETV is more prominent in HBeAg-positive patients (444
avoided LYL). CONCLUSIONS: ETV was found to be superior to both LAM mono-
therapy and LAM add-on TDF approaches in the treatment of CHB. Better clinical
outcomes may be expected with the introduction of ETV in this subgroup.
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OBJECTIVES: To indirectly compare the efficacy of telaprevir and boceprevir com-
bined with peginterferon/ribavirin in achieving sustained viral response (SVR) in
treatment-naïve and treatment-experienced patients with genotype 1 chronic
hepatitis C virus (HCV). METHODS: A systematic review of literature was con-
ducted in MEDLINE (January 2000-December 2010) to identify randomized con-
trolled trials and comparative open-label studies on the efficacy of pegylated inter-
feron (-2a and -2b)-ribavirin (PR)-based treatment in genotype 1 chronic HCV
patients. A Bayesian mixed treatment comparison (MTC), enabling indirect com-
parisons of interventions while respecting randomization, was performed on the
endpoint of SVR (HCV RNA undetectable at 24 weeks after end of treatment), as-
suming fixed study effects. For treatment-experienced patients, only previous re-
lapsers and partial responders were included, as no clinical results in prior null-
responders were available for boceprevir. RESULTS: Twelve publications were
identified and included in the systematic review and MTC. In treatment-naïve
patients, the odds ratio (OR) (posterior mean [95% credible interval]) for telaprevir
(12 weeks Response Guided Treatment (RGT) 24/48 weeks PR) and boceprevir (24
weeks  RGT 28/48 weeks PR) versus PR was respectively 3.76 [2.78-5.22] and 2.96
[2.23-4.01]. The OR for the indirect comparison of telaprevir versus boceprevir was
1.46 [0.89-2.25] (probability(OR1)0.931). In treatment-experienced patients, the
OR of telaprevir (12 weeks  48 weeks PR) and boceprevir (32 weeks  RGT 36/48
weeks PR) versus PR was respectively 12.56 [7.30-24.43] and 5.12 [2.90-10.30]. The OR
for the indirect comparison of telaprevir versus boceprevir was 2.70 [1.02-5.80]
(probability(OR1)0.978) for all patients, and 3.63 [1.12-8.97] and 1.39 [0.08-6.05]
for prior relapsers and partial responders respectively. CONCLUSIONS: In the ab-
sence of direct comparative head-to-head studies between telaprevir versus boce-
previr for the treatment of chronic HCV genotype 1 patients, MTC-based indirect
comparison suggests better efficacy for telaprevir in both treatment-naïve and
treatment-experienced patients compared to RGT boceprevir.
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OBJECTIVES: In Turkey, lamivudine (LAM) is the only reimbursed antiviral (AV)
agent for the treatment of chronic hepatitis B (CHB) patients with HBV-DNA level
107 copies/mL. Tenofovir (TDF) can be added when the patient does not respond at
week24, or viral resistance emerges. This study aimed to compare the long-term
clinical outcomes of telbivudine (ldt) with or without TDF add-on and LAM with or
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